Supriya Lifescience Ltd (SUPRIYA) is currently trading at 737.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Supriya Lifescience Limited is a major Indian manufacturer specializing in active pharmaceutical ingredients (APIs), with a robust focus on export markets. The company deals with over 39 APIs across various therapeutic segments like antihistamines, anesthetics, vitamins, anti-asthmatics, and anti-allergics. The company is capitalizing on significant growth, achieving a 20% year-over-year revenue increase in Q2 FY26. Notably, exports remain their business cornerstone, accounting for 81% of revenue, highlighting their global outreach. Supriya Lifescience has a strong market position supported by state-of-the-art manufacturing facilities and advanced R&D capabilities, allowing backward integration for 79% of its Q2 FY26 revenues. This provides operational and cost efficiencies. The company is on track to reach INR 1,000 crore revenue by Financial Year 2027, supported by a pipeline of 3-4 product launches annually and expansion into anesthetics, anti-diabetics, anti-anxiety, vitamins, and ADHD treatment markets.

Over the past 52 weeks, Supriya Lifescience Ltd has traded between a low of ₹556.85 and a high of ₹841.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Supriya Lifescience Ltd has a market capitalization of approximately 5,982.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Supriya Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.80 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Supriya Lifescience Ltd (SUPRIYA) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 5,982.69 Cr, Supriya Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Supriya Lifescience Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Supriya Lifescience Ltd is 32.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Supriya Lifescience Ltd pays dividends with a current dividend yield of 0.13%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Supriya Lifescience Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.